Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207447 | 0.93 | CYP1A2 (0.60) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL8080519 | 0.90 | CYP1A2 (0.65) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL5179125 | 0.89 | — | — | |
| SCHEMBL454467 | 0.86 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL10579794 | 0.86 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL4969658 | 0.86 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL11503388 | 0.86 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL10643742 | 0.86 | SIGMAR1 (0.62) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL1758254 | 0.85 | — | — | |
| SCHEMBL30105388 | 0.83 | SIGMAR1 (0.67) | CYP1A2SIGMAR1CELEPHX1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | claimed |
| US-9375000-B2 | Pesticidal arylpyrrolidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-9206122-B2 | Pesticidal arylpyrrolidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20150025253-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| EP-2825532-A1 | PESTICIDAL ARYLPYRROLIDINES | Bayer Intellectual Property GmbH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20140046069-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2013135724-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| EP-2616437-A1 | PESTICIDAL ARYLPYRROLIDINES | Bayer Intellectual Property GmbH (DE) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035011-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046069-A1 | PESTICIDAL ARYLPYRROLIDINES | DDT, ACHE, CAT | CYP1A2 28/4885SIGMAR1 883/4885SLC18A3 924/4885 |
| US-20150025253-A1 | PESTICIDAL ARYLPYRROLIDINES | DDT, ACHE, NPEPPS | CYP1A2 15/4885SIGMAR1 2213/4885SLC18A3 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.